Ann: MGC Derma launches Second Derma Plus CBD Product, page-37

You're right in pointing out that holders need to keep a close watch on expenditure, and I'm particularly interested in payments to directors and related entities. However, in the start-up and early development phases of any business, the costs are disproportionately high.

I would expect to see a significant reduction in outlays (except for acquisitions and capital expenditure) for all these companies in Q2 2018, and I'll be looking for income to exceed expenditure for all of them in Q4 2018.

Holders should feel free to address a 'Please Explain' to management if they are concerned about ongoing excessive expenditure.